Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lo...( Locoid Lotio...),Health

Locoid Lotion was recently introduced at the Summer American Academy of Dermatology Meeting, in Chicago, Illinois, for the treatment of mild-to-moderate atopic dermatitis in pediatric to adult patients. Triax Pharmaceuticals, LLC, the marketers of Locoid Lipocream (hydrocortisone butyrate 0.1%) a leading mid-potency brand in corticosteroids, recently launched the new product to cover larger and hairy affected areas with an elegant, non-greasy application to treat atopic dermatitis.

Crawford, NJ (PRWEB) August 12, 2008 -- A new product to treat http://www.locoid.com/ [atopic dermatitis] in adult to http://www.locoid.com/ [pediatric] patients as young as three months of age was recently introduced. Locoid Lotion, launched by http://www.triaxpharma.com/ [Triax Pharmaceuticals, LLC] - the marketers of the leading mid-potency corticosteroid brand Locoid Lipocream (hydrocortisone butyrate 0.1%) - is a new lotion vehicle especially designed to cover larger and hairy affected areas with an elegant, non-greasy application to treat milt to moderate atopic dermatitis. 1.

http://www.locoid.com/ [Atopic dermatitis] (AD) is very common in the United States. It affects nearly 15 million people (1% to 3% of adults and 10% to 20% of children).1, and accounts for 10 to 20 percent of all visits to dermatologists. The key symptom is pruritus (itching), leading to the description of AD as "the itch that rashes." Itching is fairly constant during daytime hours and worsens at night, causing sleep disturbances and discomfort. For parents of children with AD, it is the number one reason for days of missed work in the United States and it is a common cause of workplace disability for
'/>"/>